ClinicalTrials.gg
Enrolling by invitationNCT06841718FOG-EEGUpdated Feb 24, 2025

Investigating the Neural Signature of Freezing of Gait in Parkinson's Disease

An observational study in Parkinson Disease, Freezing of Gait and Basal Ganglia Diseases, sponsored by KU Leuven. Enrolling by invitation at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-24.

Sponsored by KU Leuven · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
28
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Parkinson Disease by KU Leuven — 2 open to participants now, 3 under way, none of them phase 3. Parkinson Disease · KU Leuven.

Started
2024
the only one that year
Observational
3 of 17
2 open now
Registered
16th of 17
by date

Among the 17 studies in Parkinson Disease by KU Leuven, this one is the only one that started in 2024, is one of 3 observational ones, and was the 16th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

2 of the 17 studies in Parkinson Disease by KU Leuven are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Parkinson Disease by KU Leuven, or all of them as a file.
02

Study summary

Freezing of Gait (FOG) is a disabling symptom of Parkinson's disease (PD) and a leading cause for falls. Current medical management is inadequate to alleviate FOG so there is need for improved treatments. A major draw-back in the development of better treatments for FOG is the difficulty in detecting episodes and our poor understanding of its underlying pathophysiology.

This study will investigate the cortical signature of FOG using ambulatory electroencephalography (EEG) to help improve FOG detection algorithms and provide novel insights into the underlying pathophysiology, which together will guide therapy development.

03

Conditions studied

  • Parkinson Disease
  • Freezing of Gait
  • Basal Ganglia Diseases
  • Brain Disease
  • Movement Disorders
  • Neurodegenerative Disease

Keywords

  • Parkinson's Disease
  • electroencephalography (EEG)
  • freezing of gait
  • gait problems
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

People with Parkinson's Disease who self-report to experience FOG more than once a day.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinical diagnosis of Parkinson's disease (PD) made by a Neurologist*
  2. Modified Hoehn \& Yahr (H\&Y) Stage I to IV in the ON medication state
  3. Age above 18 years*
  4. Able to walk 5 minutes while unassisted by a walker or another person (the use of a cane is allowed).*
  5. >= 21
  6. At least three hours in-between regular medication intakes to allow for stable testing time.*
  7. Self-reported FOG with a severity of at least 1 FOG episode per day, based on items 1 and 2 of the New Freezing of Gait Questionnaire, irrespective of FOG occurring ON- or OFF-medication.*
  8. Stable medication scheme for at least 7 days before enrollment.

Exclusion criteria

Exclusion Criteria:

  1. Participation in another clinical intervention study*
  2. Acute musculoskeletal or other neurological, psychiatric, or cardiovascular conditions affecting gait or any other medical condition which, in the opinion of the investigator, may prevent the participant from completing the protocol in full
  3. Unable to adhere to assessment procedures leading to missing or unusable data, as determined by the investigators
  4. Not a stable medication scheme for at least 7 days before the assessment.*
  5. Occurrence of any of the following within 3 months prior to :

    • Orthopedic surgery of the lower extremity
    • Myocardial infarction
    • Hospitalization for unstable angina
    • Coronary artery bypass graft
    • Percutaneous coronary intervention
    • Implantation of a cardiac resynchronization therapy device
    • Implantation of deep brain stimulation
  6. Substance abuse that may interfere with the patient's compliance
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
28 participants (estimated)
Patient registry
No

Groups and cohorts

  • Home assessment

    All 28 participants will undergo a single home based assessment including a gait protocol as well as administering clinimetrics and questionnaires. Patients will be tested early in the morning after at least 12 hours without the anti-parkinsonian medication (= 'partial' OFF medication) and then about 1 hour after the intake of the first morning medication dose, when the subject reports reaching self-reported ON state (= ON medication). The gait protocol consist out of A) a trajectory in the participants home from the living room towards the bathroom and back, including a 360° turn as well as a figure-8 turn and going through a doorway and B) a daily living task. All tests will be conducted in a fixed order. The protocol will be conducted as a single task, with a dual task (serial subtraction task), with voluntary stops during different parts of the trajectory, and with an auditory cue (rhythm set 10% slower then typical cadence).

06

What researchers measure

Primary outcomes

  1. Power spectral density (Watts/hertz) of beta frequencies

    The averaged power spectral density (PSD) of the beta (12-25 Hz) frequency band measured over the motor cortices during freezing of gait (FOG) episodes compared to typical gait performance in the same individual with Parkinson's disease as measured during different walking trajectories in the home setting.

    Time frame: During walking protocol (duration 15-20 minutes)

Secondary outcomes

  1. Power spectral density (Watts/hertz) of theta frequencies bands

    The averaged power spectral density (PSD) of the theta (4-7 Hz) frequency band measured over the prefrontal cortices during freezing of gait (FOG) episodes compared to typical gait performance in the same individual with Parkinson's disease as measured during different walking trajectories in the home setting.

    Time frame: During walking protocol (duration 15-20 minutes)

  2. Cross-frequency coupling between beta and theta frequency bands

    The averaged cross-frequency coupling (CFC) between the beta (12-25 Hz) and theta (4-7 Hz) frequency bands as measured over the motor and prefrontal cortices during freezing of gait (FOG) episodes compared to typical gait performance in the same individual with Parkinson's disease as measured during different walking trajectories in the home setting.

    Time frame: During walking protocol (duration 15-20 minutes)

  3. Power spectral density (Watts/hertz) and cross-frequency coupling (CFC) of beta and theta frequencies bands over other cortical areas.

    The averaged power spectral density (PSD) of the beta (12-25 Hz) and theta (4-7 Hz) frequency band measured over other cortical areas (prefrontal, motor, temporal, parietal, visual) during freezing of gait (FOG) episodes compared to typical gait performance in the same individual with Parkinson's disease as measured during different walking trajectories in the home setting.

    Time frame: During walking protocol (duration 15-20 minutes)

Other outcomes

  1. Power spectrum density and cross-frequency coupling in ON medication state

    Comparing the PSD/CFC of the primary and secondary outcomes averaged across all FOG episodes to typical gait performance during optimal ON medication state (1 hour post-medication intake)

    Time frame: During walking protocol (duration 15-20 minutes)

  2. Power spectrum density and cross-frequency coupling in OFF medication state

    Comparing the PSD/CFC of the primary and secondary outcomes averaged across all FOG episodes to typical gait performance during the practically defined OFF medication state (after minimal 12 hours overnight withdrawal).

    Time frame: During walking protocol (duration 15-20 minutes)

  3. Comparing the Power spectrum density and cross-frequency coupling in ON and OFF medication state

    Comparing the PSD/CFC averaged across all FOG episodes compared to typical gait performance between OFF and ON medication states

    Time frame: During walking protocol (duration 15-20 minutes)

  4. Comparing the Power spectrum density and cross-frequency coupling between different FOG manifestations

    Comparing the averaged PSD/CFC between the different FOG manifestations (Akinetic vs. Kinetic FOG trembling vs. Kinetic non-trembling vs. Kinetic-festination) in the ON and OFF medication states.

    Time frame: During walking protocol (duration 15-20 minutes)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — The datasets could be made available under restricted access after publication of the results, following ethical approval and a data-transfer agreement. GDPR and privacy regulations will be adhered to.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Sep 2026, 22 months after the start.

Of 381 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's planned 22 months is below that.

Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2025
First posted
Feb 24, 2025
StartActual
Nov 4, 2024
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
Feb 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06841718
Lead sponsor
KU Leuven
Responsible party
Moran Gilat (Professor, KU Leuven) — Principal investigator
First posted
Feb 24, 2025
Start date
Nov 4, 2024
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Feb 24, 2025

Study contacts

Moran Gilat, PhD
principal investigator · KU Leuven

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion